Literature DB >> 26780292

Assessment of costimulation and coinhibition in a triple parameter T cell reporter line: Simultaneous measurement of NF-κB, NFAT and AP-1.

Sabrina Jutz1, Judith Leitner1, Klaus Schmetterer2, Iago Doel-Perez3, Otto Majdic4, Katharina Grabmeier-Pfistershammer5, Wolfgang Paster1, Johannes B Huppa3, Peter Steinberger6.   

Abstract

Engagement of the T cell receptor complex reprograms T cells for proliferation, cytokine production and differentiation towards effector cells. This process depends on activating costimulatory signals and is counteracted by coinhibitory molecules. Three transcription factors, namely NF-κB, NFAT and AP-1, have a major role in inducing the transcriptional program that is required for T cell activation and differentiation. Here we describe the generation of a triple parameter reporter based on the human Jurkat T cell line, where response elements for NF-κB, NFAT and AP-1 drive the expression of the fluorescent proteins CFP, eGFP and mCherry, respectively. The emission spectra of these proteins allow simultaneous assessment of NF-κB, NFAT and AP-1 activity in response to stimulation. Ligation of the TCR complex induced moderate reporter activity, which was strongly enhanced upon coengagement of the costimulatory receptors CD2 or CD28. Moreover, we have generated and tested triple parameter reporter cells that harbor costimulatory and inhibitory receptors not endogenously expressed in the Jurkat cells. In these experiments we could show that engagement of the costimulatory molecule 4-1BB enhances NF-κB and AP-1 activity, whereas coinhibition via PD-1 or BTLA strongly reduced the activation of NF-κB and NFAT. Engagement of BTLA significantly inhibited AP-1, whereas PD-1 had little effect on the activation of this transcription factor. Our triple parameter reporter T cell line is an excellent tool to assess the effect of costimulatory and coinhibitory receptors on NF-κB, NFAT and AP-1 activity and has a wide range of applications beyond the evaluation of costimulatory pathways.
Copyright © 2015 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AP-1; Costimulation; NF-κB; NFAT; Reporter-assay; T-cell activation

Mesh:

Substances:

Year:  2016        PMID: 26780292     DOI: 10.1016/j.jim.2016.01.007

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  51 in total

1.  Chimeric Antigen Receptor Library Screening Using a Novel NF-κB/NFAT Reporter Cell Platform.

Authors:  Julian Rydzek; Thomas Nerreter; Haiyong Peng; Sabrina Jutz; Judith Leitner; Peter Steinberger; Hermann Einsele; Christoph Rader; Michael Hudecek
Journal:  Mol Ther       Date:  2018-11-20       Impact factor: 11.454

2.  Force-dependent trans-endocytosis by breast cancer cells depletes costimulatory receptor CD80 and attenuates T cell activation.

Authors:  Seungman Park; Yu Shi; Byoung Choul Kim; Myung Hyun Jo; Leilani O Cruz; Zheming Gou; Taekjip Ha; Li-Fan Lu; Daniel H Reich; Yun Chen
Journal:  Biosens Bioelectron       Date:  2020-06-17       Impact factor: 10.618

3.  Diacylglycerol kinase α inhibition cooperates with PD-1-targeted therapies to restore the T cell activation program.

Authors:  Javier Arranz-Nicolás; Miguel Martin-Salgado; Irene Adán-Barrientos; Rosa Liébana; María Del Carmen Moreno-Ortíz; Judith Leitner; Peter Steinberger; Antonia Ávila-Flores; Isabel Merida
Journal:  Cancer Immunol Immunother       Date:  2021-04-10       Impact factor: 6.968

4.  Sensing plasma membrane pore formation induces chemokine production in survivors of regulated necrosis.

Authors:  Weihong Wang; Joshua S Prokopec; Yixin Zhang; Maria Sukhoplyasova; Himaly Shinglot; Man-Tzu Wang; Andreas Linkermann; Jacob Stewart-Ornstein; Yi-Nan Gong
Journal:  Dev Cell       Date:  2022-01-10       Impact factor: 12.270

5.  Combination Immune Checkpoint Blockade Enhances IL-2 and CD107a Production from HIV-Specific T Cells Ex Vivo in People Living with HIV on Antiretroviral Therapy.

Authors:  Chris Y Chiu; Judy J Chang; Ashanti I Dantanarayana; Ajantha Solomon; Vanessa A Evans; Rachel Pascoe; Céline Gubser; Lydie Trautman; Rémi Fromentin; Nicolas Chomont; James H McMahon; Paul U Cameron; Thomas A Rasmussen; Sharon R Lewin
Journal:  J Immunol       Date:  2021-12-01       Impact factor: 5.422

6.  Targeted T cell receptor gene editing provides predictable T cell product function for immunotherapy.

Authors:  Thomas R Müller; Sebastian Jarosch; Monika Hammel; Justin Leube; Simon Grassmann; Bettina Bernard; Manuel Effenberger; Immanuel Andrä; M Zeeshan Chaudhry; Theresa Käuferle; Antje Malo; Luka Cicin-Sain; Peter Steinberger; Tobias Feuchtinger; Ulrike Protzer; Kathrin Schumann; Michael Neuenhahn; Kilian Schober; Dirk H Busch
Journal:  Cell Rep Med       Date:  2021-08-17

7.  TCR signal strength controls the differentiation of CD4+ effector and memory T cells.

Authors:  Jeremy P Snook; Chulwoo Kim; Matthew A Williams
Journal:  Sci Immunol       Date:  2018-07-20

8.  Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity.

Authors:  Olli Dufva; Jan Koski; Pilvi Maliniemi; Aleksandr Ianevski; Jay Klievink; Judith Leitner; Petri Pölönen; Helena Hohtari; Khalid Saeed; Tiina Hannunen; Pekka Ellonen; Peter Steinberger; Matti Kankainen; Tero Aittokallio; Mikko A I Keränen; Matti Korhonen; Satu Mustjoki
Journal:  Blood       Date:  2020-02-27       Impact factor: 22.113

9.  HLA-E-restricted, Gag-specific CD8+ T cells can suppress HIV-1 infection, offering vaccine opportunities.

Authors:  Hongbing Yang; Margarida Rei; Simon Brackenridge; Elena Brenna; Hong Sun; Shaheed Abdulhaqq; Michael K P Liu; Weiwei Ma; Prathiba Kurupati; Xiaoning Xu; Vincenzo Cerundolo; Edward Jenkins; Simon J Davis; Jonah B Sacha; Klaus Früh; Louis J Picker; Persephone Borrow; Geraldine M Gillespie; Andrew J McMichael
Journal:  Sci Immunol       Date:  2021-03-25

10.  Differentiation and activation of human CD4 T cells is associated with a gradual loss of myelin and lymphocyte protein.

Authors:  Judith Leitner; Kodchakorn Mahasongkram; Philipp Schatzlmaier; Karin Pfisterer; Vladimir Leksa; Supansa Pata; Watchara Kasinrerk; Hannes Stockinger; Peter Steinberger
Journal:  Eur J Immunol       Date:  2021-01-25       Impact factor: 6.688

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.